The invention refers to medicine, in particular to hepatology and virology, and can be used for treatment, including complete recovery, of patients with viral hepatitis C, including its chronic form. This invention provides a remedy for treating viral hepatitis C, that is, apoprotein lactoferrin in a monomeric form. This invention also refers to a pharmaceutical composition for treating viral hepatitis C that contains a therapeutically effective amount of apoprotein lactoferrin in a monomeric form and a pharmaceutically acceptable vehicle, filler or excipient. This invention also refers to a pharmaceutical composition for treating viral hepatitis C that includes administration of apoprotein lactoferrin in a monomeric form and to using apoprotein lactoferrin in a monomeric form for manufacturing a medication for treating viral hepatitis C. The treatment method of this invention allows to prevent virus viremia completely as a result of two or three weeks treatment, to prevent destruction of hepatocytes, affected with hepatitis C virus, together with the emission of additional number of viruses to the blood circulation system and to end the existence of the affected with virus hepatocytes with apoptosis, thus, preventing the development of hepatosis, cirrhosis and oncological damage to the liver, being the terminal stage of the main disease development.